Sydney Lepkin
👤 SpeakerAppearances Over Time
Podcast Appearances
That's compared with 5.5 pounds for the patients taking a placebo over the same time period.
And people taking Eli Lilly's experimental drug lost more weight than people taking Zetbound or Wagovi over a similar time period in other studies.
Common side effects were similar to other GLP-1 drugs, including nausea and other gastrointestinal issues.
Eli Lilly has not yet submitted retatrutide for Food and Drug Administration approval.
Speaking to reporters Tuesday, President Trump said McCary would be leaving and that a deputy would take over FDA temporarily.
During his tenure at the agency, McCary at times angered the Make America Healthy Again movement for not advancing its agenda quickly enough.
Many Maha supporters were upset when the agency approved updated COVID-19 vaccines last year.
McCary also disappointed people who oppose abortion by not completing a promised safety review of Mifepristone.
Meanwhile, he faced criticism from those looking for a more predictable approach to FDA regulation.
Before joining the Trump administration, McCary was a surgeon and health policy researcher at Johns Hopkins University School of Medicine.
Eli Lilly's new pill is called Fundeo.
Although this is the same company behind Zetbound, the blockbuster injectable obesity medicine, Eli Lilly decided not to take Zetbound's main ingredient and make it in pill form.
Instead, the company developed a new ingredient, Orfaglipron.
Daniel Skowronski, the company's chief scientific and medical officer, says until now, all of these GLP-1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions.
Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month.
Eli Lilly's new pill is called Fundeo.
Although this is the same company behind Zepbound, the blockbuster injectable obesity medicine, Eli Lilly decided not to take Zepbound's main ingredient and make it in pill form.